Harvard Business Review

JUNE 6, 2012

The secret isn't rocket science — it's a full-time commitment to the art and science of project management. PMI's Pulse of the Profession Survey shows that more than two-thirds of project-based organizations have created a dedicated Project Management Office to lead such efforts. Leveraging Executive Sponsors.

Project 19

Project Survey Budgeting Conflict of Interest 19

Harvard Business Review

JUNE 2, 2014

But as Steve Blank, Henry Chesbrough, and others have pointed out , that advantage is offset by the daunting fact that corporate innovators have to fight a war on two fronts. This is where the concept of stealth innovation can help you. To some extent, you can secure the necessary flexibility by negotiating it up front.

Innovation 15

Innovation Conflict of Interest Strategy System 15

Harvard Business Review

AUGUST 23, 2013

Fake it until you make it" might sound like a manageable way to approach your entrepreneurial efforts, but it''s also worth considering this man-riding-a-lion analogy from EnSite Solutions CEO Toby Thomas: "People look at him and think, ‘This guy''s really got it together! He''s brave!’ —Andrea Ovans.

Price 10

Price Company Sports Advertising 10

Harvard Business Review

NOVEMBER 11, 2013

The Mayo Quality Academy offers 30 courses, ranging from Lean and Six-Sigma to Human Factors and Change Management. In addition to disclosing conflicts of interest, physicians attest to participating in the QIP and report their roles (see Table 2 ). Follow the Leading Health Care Innovation insight center on Twitter @HBRhealth.

Quality 8

Quality Mayo System Six Sigma 8

Harvard Business Review

DECEMBER 4, 2017

We need tools to assess progress for external stakeholders, consumers, and managers. But I think the interesting part comes when they start to see it as an opportunity for innovations that are financially beneficial as well as socially beneficial. The result will be innovation. It’s a start.

Project 8

Project Advice Henderson Short-term 8

Harvard Business Review

SEPTEMBER 12, 2012

Equating "innovative" with new molecules misses the point: to develop clinically superior new medicines. The apparent business model of Big Pharma emphasizes the billions spent at great risk to find "innovative" and "breakthrough" new molecules that must be priced high to recover research costs that have become "unsustainable."

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

APRIL 1, 2015

Priceline’s unique “conditional purchase offer” – which allowed bidders to make low-ball offers which they were bound to honor if accepted – was an innovative solution that taught a big lesson: when underused assets are more fully exploited, everyone can win.

Innovation 8

Innovation Licensing Directory Document 8

Harvard Business Review

MARCH 2, 2017

Posen had lots of interesting things to say about what the law got right, what it made worse, and what the best criticisms of it are. His bottom line: “For a manager running a nonfinancial business, the proposed reforms to Dodd-Frank are probably a bad trade-off.” And not very much capex , not very much innovation.

Banking 8

Banking Crisis System Compliance 8

Harvard Business Review

FEBRUARY 3, 2017

By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible. For instance, 60 institutional investors, collectively managing more than $5.5

Reputation 8

Reputation Pharmaceuticals Price Business Model 8